Jo DW, et al. - A total of 64 candidates were evaluated to know the effectiveness and adverse events for 2 recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery systems in alveolar ridge preservation in this 12-week clinical trial. They found all subjects exhibiting good healing with no severe adverse events. They observed that the test group displayed non-inferiority to the control group because the lower limit of the one-sided 97.5% confidence interval in the difference between the two groups was 0.0033 (non-inferiority margin: −0.185). With regards to alterations in alveolar bone width and histomorphometric analysis, they reported no statistically significant differences between groups in Wilcoxon rank-sum test analysis.